Tag: Lantus

Insulin Pricing Crisis

The Insulin Games: A Race to Dominate the Growing Market

New long-acting insulin configurations are being developed and launched because the patent on Lantus is set to expire soon. In the United States the Lantus patent expires February 2015 and the drug’s patent expires in Europe in May 2015.
0 Shares
Lilly - Boehringer - logo

Lilly’s Investigational Basal Insulin Shows Better Results than Lantus

Newly Presented results from two Phase II studies of Eli Lilly and Boehringer Ingelheim's investigational novel basal insulin analog, LY2605541, show that that LY2605541 was associated with greater improvements of glycemic control (lowering blood sugar levels) than Lantus (insulin glargine) in patients...
0 Shares
sanofi-logo

Lantus Does Not Increase Cancer Risk, New Studies Show

Sanofi has announced new results of a large-scale epidemiological program, conducted by independent researchers in the northern European countries, at Kaiser Permanente in Northern and Southern California...
0 Shares
Amylin Lilly Logo

FDA Approves Byetta for Use with Lantus Insulin in the U.S.

The U.S. Food and Drug Administration (FDA) has approved a new use for Amylin and Eli Lilly's type 2 diabetes drug, Byetta (exenatide) injection. Byetta is now approved as an add-on therapy to insulin glargine (Lantus), with or without metformin and/or a thiazolidinedione (TZD), for adults with type 2 diabetes...
0 Shares
Novo Nordisk Logo

Novo Nordisk’s New Ultra-Long-Acting Insulin Proves Effective for Treatment of Type 2 Diabetes

Novo Nordisk's ultra-long-acting insulin degludec, an investigational basal insulin being developed, showed significant blood sugar reductions in patients with type 2 diabetes even when doses were given once-daily up to 40 hours apart, according to data presented today at the European Association for the Study of Diabetes (EASD) in Lisbon...
0 Shares
Amylin Lilly Logo

Type 2 Drug Bydureon Proves More Effective Than Other Common Diabetes Treatments

Amylin Pharmaceuticals, Eli Lilly and Alkermes announced new analyses from the DURATION-3 and DURATION-4 trials demonstrating patients treated with the investigational medication Bydureon (exenatide extended-release for injectable suspension) experienced significant improvements in select cardiovascular risk factors, in comparison to patients who received commonly prescribed diabetes treatments...
0 Shares
Novo Nordisk Logo

Novo Nordisk’s Ultra- Long- Acting Insulin Shows Lower Day-to-Day Variability Compared to Lantus

Novo Nordisk presented clinical pharmacology data for insulin degludec, an ultra-long-acting basal insulin currently under clinical investigation. The data demonstrate up to four times lower day-to-day variability in the total metabolic effect compared to insulin glargine (Lantus) in people with type 1 diabetes. The data were presented at the 46th Scientific Sessions of the European Association for the Study of Diabetes (EASD)...
0 Shares